An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Key Inclusion Criteria:
1. Participants must have biopsy-confirmed IgA Nephropathy
Key Exclusion Criteria:
clinicaltrials@biohavenpharma.com203-404-0410